MDT Form 4: EVP Marinaro has 1,052 shares withheld to cover taxes
Rhea-AI Filing Summary
Michael Marinaro, Executive Vice President, President MedSurg and Americas at Medtronic plc (MDT), reported a disposition of 1,052 ordinary shares on 08/20/2025. The shares were disposed at a reported price of $93.22 and the filing states this transaction represents shares withheld for payment of taxes upon vesting of previously reported restricted stock units. After the transaction, Marinaro beneficially owned 51,939 ordinary shares. The Form 4 is signed by an attorney-in-fact, Patricia Walesiewicz, dated 08/21/2025. The filing discloses only the withholding tax disposition and current beneficial ownership.
Positive
- Disclosure of tax-withholding disposal for vested restricted stock units provides transparency into executive equity changes
- Post-transaction beneficial ownership is reported (51,939 shares), giving a clear picture of remaining insider holdings
- Form 4 executed and signed by an authorized attorney-in-fact, indicating formal filing procedures were followed
Negative
- None.
Insights
TL;DR: Routine tax-withholding disposal of vested RSUs; small change relative to total holdings, limited market impact.
The Form 4 documents a common corporate practice where restricted stock units vest and the company withholds a portion of shares to satisfy tax obligations. The reported disposal of 1,052 shares at $93.22 reduced the reporting person's beneficial ownership to 51,939 shares. There is no indication of open-market selling for investment purposes or of additional derivative activity. For investors, this is administrative in nature and provides transparency on executive equity after vesting.
TL;DR: Proper Section 16 disclosure of tax-withholding on vested RSUs; filing appears complete for the disclosed transaction.
The Form 4 clearly identifies the reporting person, relationship to issuer, transaction date, and that the shares were withheld to pay taxes on vested RSUs. The entry includes the post-transaction beneficial ownership figure and is signed by an authorized attorney-in-fact. This meets routine Section 16 reporting expectations. No governance concerns, departures, or compensatory anomalies are noted within the provided text.
FAQ
What transaction did Michael Marinaro report on Form 4 for MDT?
At what price were the shares disposed according to the filing?
How many Medtronic shares does Marinaro beneficially own after the transaction?
Who signed the Form 4 and when was it signed?
Was the disposition described as a sale or another type of transaction?